A Phase 3 interventional study of Celecoxib+Pregabalin+Vitamin B fixed dose and Celecoxib + Vitamin B fixed dose in Chronic Low-back Pain, sponsored by Laboratorios Silanes S.A. de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-04.
Sponsored by Laboratorios Silanes S.A. de C.V. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Low Back Pain with a site in Mexico — 2 open to participants now, 2 under way, none of them phase 3. Low Back Pain · Mexico.
Among the 11 studies in Low Back Pain with a site in Mexico, this one is the only one that started in 2024, is one of 3 in phase 3, and was the 9th registered.
2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.
Browse Low Back Pain studies →2 of the 11 studies in Low Back Pain with a site in Mexico are open now. Recruiting first, the newest first:
ISSSTE Hospital Regional "Gral. Ignacio Zaragoza" · Sites in Mexico
Ages 18–75
Armando Tonatiuh Avila Garcia · Sites in Mexico
Ages 18–80
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 192 is above the median of 60 across 2,366 interventional studies indexed under Low Back Pain.
Median enrollment 177 across the 8 interventional studies, 50 across the 3 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 11 have an industry lead sponsor. The 9 most frequent:
Laboratorios Silanes S.A. de C.V. is the lead sponsor of 45 studies on the registry; 1 is open to participants now.
Laboratorios Silanes S.A. de C.V. has 2 studies filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
1 of the studies in Low Back Pain with a site in Mexico that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07929623ISSSTE Hospital Regional "Gral. Ignacio Zaragoza"Fluoroscopy-Guided Lumbar Facet Block for Chronic Low Back Pain | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Low Back Pain with a site in Mexico, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and security of the drug combination of Celecoxib / Pregabalin / Vitamin B versus Celecoxib + Vitamin B, versus Pregabalin + Vitamin B in the treatment of chronic low back pain.
Researchers will compare the fixed-dose combination of Celecoxib/Pregabalin/Vitamin B versus Celecoxib + Vitamin B versus Pregabalin + Vitamin B for chronic low back pain. The adverse events related to the interventions would be registered in each follow up visit.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered orally, 1 tablet + 1 capsule a day, for 3 months.
Drug: Celecoxib+Pregabalin+Vitamin B fixed dose
Administered orally, 1 capsule + 1 tablet a day, for 3 months
Drug: Celecoxib + Vitamin B fixed dose
Administered orally, 1 capsule + 1 tablet a day, for 3 months
Drug: Pregabalin + Vitamin B fixed dose
One tablet of 200 mg / 150 mg / 100 mg / 50 mg / 0.50 mg + 1 capsule of placebo once a day
Also known as: Cele+Pre+Vit B
One capsule of 200 mg + 1 tablet of 100 mg / 50 mg / 0.50 mg once a day
Also known as: Cele+Vit B
One capsule of 150 mg + 1 tablet of 100 mg / 50 mg / 0.50 mg once a day
Also known as: Pre+Vit B
Comparison of the percentage change of Celecoxib / Pregabalin / Vitamin B Combination versus Celecoxib + Vitamin B versus Pregabalin + Vitamin B in the management of chronic low back pain through the visual analog pain scale (VAS).
The visual analog pain scale (VAS) is a straight line in which one end signifies absence of pain and the other means the worst pain imaginable. The researcher will apply the VAS scale to each patient at each visit to assess pain intensity. At the end of the clinical trial the change porcentage will be measured and compared between treatment groups.
Time frame: 3 months
Number of participants with treatment-related adverse events through the patient's diary record.
To describe the frequency, intensity and causality of the adverse events presented during the clinical trial by treatment group. The adverse events will be registered by the patient in the diary record. Each adverse event will be followed up at the discretion of the researcher.
Time frame: 3 months
To describe the sociodemographic characteristics of the patients included in the study by treatment group
A general description of sex, age, race, weight, height and BMI. * Body weight: should be obtained on a scale, with the patient without shoes, in a standing position it would be recorded in kilograms. * Height: must be obtained with a stadimeter, with the patient without shoes, in a standing position, the record will be in meters Height will be measured only at visit 0, and will be taken as a reference for measurement of BMI. * BMI: calculated with the formula: Weight/height2 and will be recorded in kg/m2. Weight and height will be combined to report BMI in kg/m\^2
Time frame: 3 months
Assess the proportion of patients who reported >30% improvement in pain intensity measured through VAS at 12 weeks per treatment group
The visual analog pain scale (VAS) is a straight line in which one end signifies absence of pain and the other means the worst pain imaginable. The researcher will apply the VAS scale to each patient at each visit to assess pain intensity. At the end of the clinical trial the proportion of patiens with an improvement of pain \>30% will be reported and compared between treatment groups.
Time frame: 3 months
Assess the proportion of patients who reported >50% improvement in pain intensity measured through VAS at 12 weeks per treatment group
The visual analog pain scale (VAS) is a straight line in which one end signifies absence of pain and the other means the worst pain imaginable. The researcher will apply the VAS scale to each patient at each visit to assess pain intensity. At the end of the clinical trial the proportion of patiens with an improvement of pain \>50% will be reported and compared between treatment groups.
Time frame: 3 months
Assess at what time of follow-up the greatest reduction in pain intensity was achieved, measured through VAS, per treatment group.
The visual analog pain scale (VAS) is a straight line in which one end signifies absence of pain and the other means the worst pain imaginable. The researcher will apply the VAS scale to each patient at each visit to assess time of greatest reduction in pain intensity.
Time frame: 3 months
Assess and compare the degree of physical disability due to low back pain, measured through the Oswestry disability questionnaire at 4 and 12 weeks per treatment group.
The Oswestry questionnaire has been designed to give us information as to how the back pain has affected the ability to manage everyday life of patients, it classifies QOL as: no disability, mild disability, moderate disability, severe disability and completely disabled. The disability degree would be compared.
Time frame: 3 months
Assess and compare the degree of disability to perform daily activities due to low back pain, reported through Roland-Morris questionnaire at 4 and 12 weeks per group treatment
The Roland-Morris questionnaire has been designed to assess the activities of daily living functional mobility pain. A maximum score of 24 indicates the greatest degree of disability from pain. The disability degree would be compared.
Time frame: 3 months
Assess and compare health status through the 5-level, 5-dimensions EuroQol questionnaire (EQ-5D-5L) at 12 weeks from baseline in each group of treatment
The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS)The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'The best health you can image' and 'The worst health you can image'.
Time frame: 3 months
Report the number of patients that required dose escalation
Dose escalation criteria: 1. Increase in VAS values compared to the previous visit. 2. Use of rescue medication at least in three consecutive occasions. 3. Percentage of adherence to treatment ≥ 80% The researcher will assess the need for dose escalation or not in each visit.
Time frame: 3 months
Report the number of patients who require the use of rescue medication during the clinical trial by treatment group.
The rescue medication will be tramadol 50 mg: - The patient that considers the need for rescue medication must call the doctor, who will be in charge of applying the VAS scale by telephone. If the doctor considers it necessary, the taking of the rescue medication will be indicated.
Time frame: 3 months
Report the number of patients who presented therapeutic failure during the study among the treatment groups
Therapeutic failure will be defined by the principal researcher previous medical consult, the following criteria must be present: * Increase in the parameters of the VAS scale at 12 weeks from baseline * ≥80% to adherence to treatment * The consumption of at least 2 doses of the designated group treatment * The need of use of the rescue medication during 24 consecutive hours * The absence of comorbidities that could increase the pain (knew traumatism during the clinical trial)
Time frame: 3 months
To report the percentage of therapeutic adherence at 12 weeks of intervention by group of treatment.
Therapeutic adherence will be defined by the principal researcher. Adherence to treatment will be defined as a consumption ≥ 80% of the doses that the patient should have ingested at the time of the corresponding evaluation.
Time frame: 3 months
Blood concentration of BUN of the patients included in the study by treatment group
A blood sample will be taken in each visit reporting BUN parameters. Comparisons of serum levels between groups will be made.
Time frame: 3 months
Blood concentration of glucose of the patients included in the study by treatment group
A blood sample will be taken in each visit reporting glucose parameters. Comparisons of serum levels between groups will be made.
Time frame: 3 months
Blood concentration of urea of the patients included in the study by treatment group
A blood sample will be taken in each visit reporting urea parameters. Comparisons of serum levels between groups will be made.
Time frame: 3 months
Blood concentration of creatinin of the patients included in the study by treatment group
A blood sample will be taken in each visit reporting creatinin parameters. Comparisons of serum levels between groups will be made.
Time frame: 3 months
Blood concentration of Alkaline Phosphatase of the patients included in the study by treatment group
A blood sample will be taken in each visit reporting Alkaline Phosphatase parameters. Comparisons of serum levels between groups will be made.
Time frame: 3 months
Blood concentration of total bilirrubin of the patients included in the study by treatment group
A blood sample will be taken in each visit reporting total bilirrubin parameters. Comparisons of serum levels between groups will be made.
Time frame: 3 months
Plan to share: No
Ran from Apr 2024 to primary completion in Jan 2025, 8 months.
Of 35 phase 3 interventional studies under Low Back Pain, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 40. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Laboratorios Silanes S.A. de C.V. →